Literature DB >> 27344488

Discovery and development of natural product oridonin-inspired anticancer agents.

Ye Ding1, Chunyong Ding1, Na Ye1, Zhiqing Liu1, Eric A Wold1, Haiying Chen1, Christopher Wild1, Qiang Shen2, Jia Zhou3.   

Abstract

Natural products have historically been, and continue to be, an invaluable source for the discovery of various therapeutic agents. Oridonin, a natural diterpenoid widely applied in traditional Chinese medicines, exhibits a broad range of biological effects including anticancer and anti-inflammatory activities. To further improve its potency, aqueous solubility and bioavailability, the oridonin template serves as an exciting platform for drug discovery to yield better candidates with unique targets and enhanced drug properties. A number of oridonin derivatives (e.g. HAO472) have been designed and synthesized, and have contributed to substantial progress in the identification of new agents and relevant molecular mechanistic studies toward the treatment of human cancers and other diseases. This review summarizes the recent advances in medicinal chemistry on the explorations of novel oridonin analogues as potential anticancer therapeutics, and provides a detailed discussion of future directions for the development and progression of this class of molecules into the clinic.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Anticancer agents; Chemical biology; Diterpenoids; Drug discovery; Natural product; Oridonin

Mesh:

Substances:

Year:  2016        PMID: 27344488      PMCID: PMC5003635          DOI: 10.1016/j.ejmech.2016.06.015

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  122 in total

1.  Oridonin nanosuspension enhances anti-tumor efficacy in SMMC-7721 cells and H22 tumor bearing mice.

Authors:  Haiyan Lou; Lei Gao; Xinbing Wei; Zhen Zhang; Dandan Zheng; Dianrui Zhang; Xiumei Zhang; Ying Li; Qiang Zhang
Journal:  Colloids Surf B Biointerfaces       Date:  2011-05-27       Impact factor: 5.268

2.  A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma.

Authors:  Jaffer A Ajani; Yixing Jiang; Josephine Faust; Baochong B Chang; Linus Ho; James C Yao; Steven Rousey; Shaker Dakhil; Richard C Cherny; Catherine Craig; Archie Bleyer
Journal:  Invest New Drugs       Date:  2006-07       Impact factor: 3.850

3.  Cytotoxic ent-kaurane diterpenoids from Isodon rubescens var. lushiensis.

Authors:  Xiao Luo; Jian-Xin Pu; Wei-Lie Xiao; Yong Zhao; Xue-Mei Gao; Xiao-Nian Li; Hai-Bo Zhang; Yuan-Yuan Wang; Yan Li; Han-Dong Sun
Journal:  J Nat Prod       Date:  2010-06-25       Impact factor: 4.050

4.  Discovery of potent anticancer agent HJC0416, an orally bioavailable small molecule inhibitor of signal transducer and activator of transcription 3 (STAT3).

Authors:  Haijun Chen; Zhengduo Yang; Chunyong Ding; Ailian Xiong; Christopher Wild; Lili Wang; Na Ye; Guoshuai Cai; Rudolfo M Flores; Ye Ding; Qiang Shen; Jia Zhou
Journal:  Eur J Med Chem       Date:  2014-05-22       Impact factor: 6.514

5.  Novel nitrogen-enriched oridonin analogues with thiazole-fused A-ring: protecting group-free synthesis, enhanced anticancer profile, and improved aqueous solubility.

Authors:  Chunyong Ding; Yusong Zhang; Haijun Chen; Zhengduo Yang; Christopher Wild; Lili Chu; Huiling Liu; Qiang Shen; Jia Zhou
Journal:  J Med Chem       Date:  2013-06-19       Impact factor: 7.446

Review 6.  PEG drugs: an overview.

Authors:  R B Greenwald
Journal:  J Control Release       Date:  2001-07-06       Impact factor: 9.776

Review 7.  Terpenoids: natural products for cancer therapy.

Authors:  Min Huang; Jin-Jian Lu; Ming-Qing Huang; Jiao-Lin Bao; Xiu-Ping Chen; Yi-Tao Wang
Journal:  Expert Opin Investig Drugs       Date:  2012-10-23       Impact factor: 6.206

8.  Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.

Authors:  Xitao Li; Yingying Zuo; Guanghui Tang; Yan Wang; Yiqing Zhou; Xueying Wang; Tianlin Guo; Mengying Xia; Ning Ding; Zhengying Pan
Journal:  J Med Chem       Date:  2014-06-10       Impact factor: 7.446

9.  Enhanced anti-fibrogenic effects of novel oridonin derivative CYD0692 in hepatic stellate cells.

Authors:  Fredrick J Bohanon; Xiaofu Wang; Brittany M Graham; Anesh Prasai; Sadhashiva J Vasudevan; Chunyong Ding; Ye Ding; Geetha L Radhakrishnan; Cristiana Rastellini; Jia Zhou; Ravi S Radhakrishnan
Journal:  Mol Cell Biochem       Date:  2015-09-07       Impact factor: 3.396

Review 10.  Profile and potential of ixabepilone in the treatment of pancreatic cancer.

Authors:  Brandon G Smaglo; Michael J Pishvaian
Journal:  Drug Des Devel Ther       Date:  2014-07-14       Impact factor: 4.162

View more
  40 in total

1.  Regio- and Stereospecific Synthesis of Oridonin D-Ring Aziridinated Analogues for the Treatment of Triple-Negative Breast Cancer via Mediated Irreversible Covalent Warheads.

Authors:  Ye Ding; Dengfeng Li; Chunyong Ding; Pingyuan Wang; Zhiqing Liu; Eric A Wold; Na Ye; Haiying Chen; Mark A White; Qiang Shen; Jia Zhou
Journal:  J Med Chem       Date:  2018-03-20       Impact factor: 7.446

2.  A thiazole-derived oridonin analogue exhibits antitumor activity by directly and allosterically inhibiting STAT3.

Authors:  Xiaofei Shen; Lin Zhao; Peihao Chen; Yanqiu Gong; Dingdong Liu; Xia Zhang; Lunzhi Dai; Qingxiang Sun; Jizhong Lou; Zhong Jin; Baohua Zhang; Dawen Niu; Ceshi Chen; Xiangbing Qi; Da Jia
Journal:  J Biol Chem       Date:  2019-10-08       Impact factor: 5.157

3.  Function-Oriented and Modular (+/-)-cis-Pseudoguaianolide Synthesis: Discovery of New Nrf2 Activators and NF-κB Inhibitors.

Authors:  Fabien Emmetiere; Ranjala Ratnayake; Henry A M Schares; Katherine F M Jones; Emily Bevan-Smith; Hendrik Luesch; Daniel A Harki; Alexander J Grenning
Journal:  Chemistry       Date:  2021-02-26       Impact factor: 5.236

4.  Biophysical and biochemical properties of PHGDH revealed by studies on PHGDH inhibitors.

Authors:  Yuping Tan; Xia Zhou; Yanqiu Gong; Kun Gou; Youfu Luo; Da Jia; Lunzhi Dai; Yinglan Zhao; Qingxiang Sun
Journal:  Cell Mol Life Sci       Date:  2021-12-31       Impact factor: 9.261

5.  Combination of oridonin and TRAIL induces apoptosis in uveal melanoma cells by upregulating DR5.

Authors:  Xin Hua; Peng Wu; Guo-Sheng Gao; Xiao-Lei Ye
Journal:  Int J Ophthalmol       Date:  2021-12-18       Impact factor: 1.779

6.  Identification of a 3-β-homoalanine conjugate of brusatol with reduced toxicity in mice.

Authors:  Nicky Hwang; Yonggang Pei; Jason Clement; Erle S Robertson; Yanming Du
Journal:  Bioorg Med Chem Lett       Date:  2020-09-21       Impact factor: 2.823

Review 7.  Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine.

Authors:  Hua Luo; Chi Teng Vong; Hanbin Chen; Yan Gao; Peng Lyu; Ling Qiu; Mingming Zhao; Qiao Liu; Zehua Cheng; Jian Zou; Peifen Yao; Caifang Gao; Jinchao Wei; Carolina Oi Lam Ung; Shengpeng Wang; Zhangfeng Zhong; Yitao Wang
Journal:  Chin Med       Date:  2019-11-06       Impact factor: 5.455

Review 8.  Oridonin and its derivatives for cancer treatment and overcoming therapeutic resistance.

Authors:  Xi Liu; Jimin Xu; Jia Zhou; Qiang Shen
Journal:  Genes Dis       Date:  2020-07-05

Review 9.  Oridonin, a Promising ent-Kaurane Diterpenoid Lead Compound.

Authors:  Dahong Li; Tong Han; Jie Liao; Xu Hu; Shengtao Xu; Kangtao Tian; Xiaoke Gu; Keguang Cheng; Zhanlin Li; Huiming Hua; Jinyi Xu
Journal:  Int J Mol Sci       Date:  2016-08-24       Impact factor: 5.923

10.  Effects of dietary supplementation with oridonin on the growth performance, relative organ weight, lymphocyte proliferation, and cytokine concentration in broiler chickens.

Authors:  Qiu Jue Wu; Xiao Chuan Zheng; Tian Wang; Tie Ying Zhang
Journal:  BMC Vet Res       Date:  2018-01-31       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.